

PATENT
ATTORNEY DOCKET NO.: 056291-5039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

PEARS et al.

U.S. Application No.: 09/889,414

Filed: November 13, 2001

FOR: DRUG COMBINATIONS COMPRISING
(E)-7-[4-(4-FLUOROPHENYL)-6-
ISOPROPYL-2-
[METHYL(METHYLSULFONYL)
AMINO]PYRIMIDIN-5-YL](3R,5S)-
3,DIHYDROXYHEPT-6-ENOIC ACID AND
AN INHIBITOR, INDUCER OR
SUBSTRATE OF P450 ISOENZYME 3A4

Group Art Unit: 1654

Examiner: Meller, Michael V.

Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **Mail Stop** _____
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Date: March 10, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

Attached is a Form PTO-1449 listing the enclosed documents.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Please charge the Rule 17(p) official fee required by Rule 97(c) to our Deposit

Account No. 50-0310 under Order No. 056291-5039.

03/12/2004 BABRAHA1 00000082 500310 09889414


02 FC:1806 180.00 DA

1-WA/2154037.1

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP




Date: March 10, 2004
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket No.	Client Ref.
	056291-5039	
	Applicant: PEARS et al.	
	Appln. No.: 09/889,414	
	Filing Date: November 13, 2001	
Date: March 10, 2004	Page 1 of 1	Examiner: Meller, Michael V. Group Art Unit: 1654



U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclosed	No
	GR								
	HR								
	IR								
	JR								
	KR								
	LR								
	MR								
	NR								
	OR								
	PR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
QR	Hunninghake, "HMG CoA reductase inhibitors", Current Opinion in Lipidology 1992; 3:22-28 (cited in the specification at page 3, lines 11-12).							
RR	Miller et al., "Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)", Clin Pharmacokinet 1998 Feb; 34(2): 155-162.							
SR	Williams et al., "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors", Clin Pharmacokinet 2002; 41(5): 343-370.							
TR								
UR								
VR								
WR								
XR								

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	